Skip links
Nationwide Home Infusion & Nursing Network

For At-Home Infusions, Patient Training, and Patient Support

Contact Us to Learn More

At Orsini, we have a long history of providing quality home infusion services to rare and chronic disease patients through our comprehensive nursing network. Overseen by Orsini nurse managers, this network acts as an extension of our team, leading to seamless internal communication and patient care coordination.​

About Us

Highly Skilled Nursing Team

These highly skilled RNs receive disease- and therapy-specific training, developed together with our biopharma partners, from Orsini nurse case managers. Their visits are customized to fit the needs of each patient who chooses to receive in-home infusions, and we strive to foster ongoing patient-nurse relationships to maintain consistency in care. Where appropriate, our nursing network can also provide therapy self-administration training directly to patients.​

Our nationwide nursing and payor coverage allows us to reach patients whenever and wherever they need care, at all stages of life, and the Orsini Nurse Support Hotline puts nursing help at the tips of patients’ and prescribers’ fingers.

Interested in Joining Our Nursing Network?

Drugs with home health nursing available

Full Name Adzynma (ADAMTS13, recombinant-krhn)
Drug Adzynma
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP)
Disease Congenital thrombotic thrombocytopenic purpura (c-TTP)
Therapeutic Area Hematology
Enrollment Form Link Enrollment Form
Phone Number 800-720-0789
Fax Number 877-251-0709
Product Website adzynma.com

Full Name Aldurazyme® (laronidase)
Drug Aldurazyme
Manufacturer Genzyme Corporation
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms
Disease Mucopolysaccharidosis I
Therapeutic Area Neurology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website aldurazyme.com/healthcare

Full Name Amondys 45™ (casimersen)
Drug Amondys 45
Manufacturer Sarepta Therapeutics, Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping
Disease Duchenne Muscular Dystrophy (DMD)
Therapeutic Area Neurology
Enrollment Form Link Enrollment Form
Phone Number 800-356-5034
Fax Number 877-339-4602
Product Website amondys45.com

Full Name Amvuttra® (vutrisiran)
Drug Amvuttra
Manufacturer Alnylam Pharmaceuticals, Inc.
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Disease Hereditary ATTR amyloidosis (hATTR) - Polyneuropathy (PN)
Therapeutic Area Neurology
Enrollment Form Link Enrollment Form
Phone Number 800-372-9581
Fax Number 877-349-7938
Product Website amvuttrahcp.com

Full Name Berinert® [C1 esterase inhibitor (human)]
Drug Berinert
Manufacturer CSL Behring
Route of Administration Intravenous
Site of Care Home
Approved Indication Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website berinert.com/professional

Full Name Cerezyme® (imiglucerase)
Drug Cerezyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly
Disease Gaucher Type I Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website cerezyme.com/hcp

Full Name Cinryze® [C1 esterase inhibitor (human)]
Drug Cinryze
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Routine prophylaxis against angioedema attacks in adults, adolescents, and pediatric patients (6 years of age and older) with Hereditary Angioedema (HAE)
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website cinryze.com/hcp

Full Name Crysvita® (burosumab-twza)
Drug Crysvita
Manufacturer Kyowa Kirin North America
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older and FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older
Disease Tumor-induced Osteomalacia (TIO); X-linked Hypophosphatemia (XLH)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Enrollment Form
Phone Number 800-240-7614
Fax Number 877-793-4897
Product Website crysvitahcp.com

Full Name Elaprase® (idursulfase)
Drug Elaprase
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)
Disease Mucopolysaccharidosis II
Therapeutic Area Neurology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website elaprase.com/hcp

Full Name Elfabrio® (pegunigalsidase alfa-iwxj)
Drug Elfabrio
Manufacturer Chiesi
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adults with confirmed Fabry disease
Disease Fabry disease
Therapeutic Area Neurology, Nephrology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 833-656-1056
Fax Number 636-355-3610
Product Website hcp.elfabrio.com

Full Name Evkeeza® (evinacumab-dgnb)
Drug Evkeeza
Manufacturer Regeneron Pharmaceuticals
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)
Disease Homozygous Familial Hypercholesterolemia (HoFH)
Therapeutic Area Cardiology
Enrollment Form Link Enrollment Form
Phone Number 800-645-4142
Fax Number 877-473-0199
Product Website evkeezahcp.com

Full Name Exondys 51® (eteplirsen)
Drug Exondys 51
Manufacturer Sarepta Therapeutics, Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping
Disease Duchenne Muscular Dystrophy (DMD)
Therapeutic Area Neurology
Enrollment Form Link Enrollment Form
Phone Number 800-356-5034
Fax Number 877-339-4602
Product Website exondys51.com

Full Name Fabrazyme® (agalsidase beta)
Drug Fabrazyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease
Disease Fabry disease
Therapeutic Area Neurology, Nephrology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website hcp.fabrazyme.com

Full Name Kalbitor® (ecallantide)
Drug Kalbitor
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Subcutaneous
Site of Care Home
Approved Indication Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website kalbitor.com/hcp

Full Name Kanuma® (sebelipase alfa)
Drug Kanuma
Manufacturer Alexion Pharmaceuticals, a subsidiary of AstraZeneca
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency
Disease Lysosomal Acid Lipase Deficiency (LAL-D)
Therapeutic Area Neurology, Genetics
Enrollment Form Link Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website kanuma.com/hcp

Full Name Lumizyme® (alglucosidase alfa)
Drug Lumizyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Patients with Pompe disease (GAA deficiency)
Disease Pompe Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Enrollment Form Link
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website lumizyme.com

Full Name Naglazyme® (galsulfase)
Drug Naglazyme
Manufacturer BioMarin Pharmaceutical Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Patients with Mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy Syndrome)
Disease Mucopolysaccharidosis VI
Therapeutic Area Neurology, Genetics
Enrollment Form Link Naglazyme Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website naglazyme.com

Full Name Nexviazyme® (avalglucosidase alfa-ngpt)
Drug Nexviazyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
Disease Pompe Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Nexviazyme Enrollment Form Link
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website nexviazyme.com

Full Name Onpattro® (patisiran)
Drug Onpattro
Manufacturer Alnylam Pharmaceuticals
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Disease Hereditary ATTR amyloidosis (hATTR) - Polyneuropathy (PN)
Therapeutic Area Neurology
Enrollment Form Link Onpattro Start Form
Phone Number 800-690-8236
Fax Number 877-445-8481
Product Website onpattro.com

Full Name Oxlumo® (lumasiran)
Drug Oxlumo
Manufacturer Alnylam Pharmaceuticals
Route of Administration Subcutaneous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients
Disease Primary Hyperoxaluria Type 1 (PH1)
Therapeutic Area Nephrology
Enrollment Form Link Oxlumo Enrollment Form
Phone Number 800-460-5217
Fax Number 877-276-8563
Product Website oxlumo.com

Full Name PEDMARK® (sodium thiosulfate injection)
Drug Pedmark
Manufacturer Fennec Pharmaceuticals
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors
Disease Ototoxicity associated with cisplatin
Therapeutic Area Otolaryngology
Enrollment Form Link Pedmark Enrollment Form
Phone Number 800-385-8596
Fax Number 877-694-2545
Product Website pedmark.com

Full Name Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat)
Drug Pombiliti & Opfolda
Manufacturer Amicus Therapeutics
Route of Administration Intravenous and oral
Site of Care Home or Healthcare Facility
Approved Indication The treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT)
Disease Pompe Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Pombiliti & Opfolda Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website pombilitiopfolda.com

Full Name Ruconest® [C1 esterase inhibitor (recombinant)]
Drug Ruconest
Manufacturer Pharming Group
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE)
Disease Hereditary Angioedema (HAE)
Therapeutic Area Allergy & Immunology
Enrollment Form Link Ruconest Patient Enrollment Form
Phone Number 800-356-4252
Fax Number 847-631-6918
Product Website ruconest.com

Full Name Tzield® (teplizumab-mzwv)
Drug Tzield
Manufacturer Sanofi
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D
Disease Type 1 Diabetes (T1D)
Therapeutic Area Endocrinology & Bone Specialty
Enrollment Form Link Tzield Enrollment Form
Phone Number 800-670-5321
Fax Number 877-655-4364
Product Website tzield.com

Full Name Viltepso® (viltolarsen)
Drug Viltepso
Manufacturer NS Pharma
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Disease Duchenne Muscular Dystrophy (DMD)
Therapeutic Area Neurology
Enrollment Form Link Viltepso Enrollment Form
Phone Number 800-759-0445
Fax Number 877-286-3620
Product Website viltepso.com

Full Name Vimizim® (elosulfase alfa)
Drug Vimizim
Manufacturer BioMarin Pharmaceutical Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)
Disease Mucopolysaccharidosis IVA
Therapeutic Area Neurology, Genetics
Enrollment Form Link Vimizim Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website vimizim.com

Full Name Vpriv® (velaglucerase alfa)
Drug Vpriv
Manufacturer Takeda Pharmaceuticals U.S.A., Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease
Disease Gaucher Type I Disease
Therapeutic Area Neurology, Genetics
Enrollment Form Link Vpriv Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website hcp.vpriv.com

Full Name Vyepti® (eptinezumab-jjmr)
Drug Vyepti
Manufacturer Lundbeck
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The preventive treatment of migraine in adults
Disease Migraine
Therapeutic Area Neurology
Enrollment Form Link Vyepti Enrollment Form
Phone Number 800-259-7145
Fax Number 877-892-3019
Product Website vyeptihcp.com

Full Name Vyondys 53® (golodirsen)
Drug Vyondys 53
Manufacturer Sarepta Therapeutics, Inc.
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication The treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping
Disease Duchenne Muscular Dystrophy (DMD)
Therapeutic Area Neurology
Enrollment Form Link Vyondys 53 Enrollment Form
Phone Number 800-356-5034
Fax Number 877-339-4602
Product Website vyondys53.com

Full Name Xenpozyme® (olipudase alfa-rpcp)
Drug Xenpozyme
Manufacturer Sanofi Genzyme
Route of Administration Intravenous
Site of Care Home or Healthcare Facility
Approved Indication Treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients
Disease Acid Sphingomyelinase Deficiency (ASMD)
Therapeutic Area Neurology, Genetics
Enrollment Form Link Xenpozyme Enrollment Form
Phone Number 800-240-9572
Fax Number 877-220-7581
Product Website xenpozyme.com